Although FOXO TFs themselves may not represent straight forward drug targets, the accumulating evidence suggests that the signaling network involving BCR ABL/PI3K/AKT/mTOR/FOXO/BCL6 is critical for the quiescence and survival of CML stem/progenitor cells and may be targeted for therapy. This evidence concerns the gene BCL6 and chronic myelogenous leukemia, BCR-ABL1 positive.